Harvard Bioscience, Inc. Share Price
Stocks
HBIO
US4169062043
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
21:00:00 11/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 9.680 USD | +4.54% |
|
+12.43% | +44.74% |
| 11-10 | Harvard Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 11-10 | Harvard Bioscience, Inc., Q3 2026 Earnings Call, Nov 10, 2026 |
| Market Cap | 44.07M 39.72M 36.69M 33.17M 62.76M 4.13B 64.31M 440M 175M 2.21B 165M 162M 7.04B | P/E 2026 * |
-4.08x | P/E 2027 * | -15.2x |
|---|---|---|---|---|---|
| Enterprise Value | 44.07M 39.72M 36.69M 33.17M 62.76M 4.13B 64.31M 440M 175M 2.21B 165M 162M 7.04B | EV / Sales 2026 * |
0.49x | EV / Sales 2027 * | 0.46x |
| Free-Float |
90.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| HBIO | Delayed | |
CBOE
| HBIO | Real-time |
Last Transcript: Harvard Bioscience, Inc.
| 1 day | +4.54% | ||
| 1 week | +12.43% | ||
| Current month | +8.76% | ||
| 1 month | +17.48% | ||
| 3 months | +57.91% | ||
| 6 months | +41.52% | ||
| Current year | +44.74% |
| 1 week | 8.11 |  | 10.2 |
| 1 month | 7.9 | | 10.2 |
| Current year | 4 | | 10.2 |
| 1 year | 4 | | 10.2 |
| 3 years | 2.81 | | 55.6 |
| 5 years | 2.81 | | 81.2 |
| 10 years | 2.81 | | 87.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Duke
CEO | Chief Executive Officer | 55 | 27/07/2025 |
Mark Frost
DFI | Director of Finance/CFO | 63 | 11/05/2025 |
Diane Houston
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Katherine Eade
BRD | Director/Board Member | 52 | 23/10/2017 |
John Duke
BRD | Director/Board Member | 55 | 01/06/2025 |
Robert Gagnon
BRD | Director/Board Member | 52 | 15/07/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/03/26 | Free | Chief Executive Officer | 75,000 | 0.1677% | ||
| 20/03/26 | Free | Chief Financial Officer | 30,000 | 0.0671% | ||
| 17/03/26 | Buy | Director | 10,000 | 0.0224% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.54% | +12.43% | +59.34% | -75.80% | 42.15M | |
| -0.07% | +1.64% | +22.37% | +60.05% | 266B | |
| -0.34% | +0.16% | +9.05% | +19.45% | 166B | |
| -0.11% | -6.76% | -21.43% | +62.00% | 156B | |
| +0.96% | -1.51% | -55.97% | -12.47% | 64.79B | |
| +1.73% | +6.48% | +24.25% | +64.79% | 59.81B | |
| +1.35% | -2.97% | -2.05% | -8.59% | 53.3B | |
| -0.52% | -0.12% | +18.42% | +63.13% | 50.15B | |
| -0.26% | -1.89% | +1.90% | +84.62% | 49.47B | |
| -0.97% | +0.71% | +21.95% | +84.00% | 46.72B | |
| Average | +0.62% | +1.10% | +7.78% | +34.12% | 91B | |
| Weighted average by Cap. | +0.05% | -0.39% | +4.24% | +46.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 90.14M 81.24M 75.06M 67.85M 128M 8.45B 132M 900M 359M 4.53B 338M 331M 14.41B | 95.4M 85.98M 79.44M 71.81M 136M 8.95B 139M 952M 379M 4.79B 358M 350M 15.25B |
| Net income | -9.6M -8.65M -7.99M -7.23M -13.67M -900M -14.01M -95.8M -38.18M -482M -36.03M -35.26M -1.53B | -3.5M -3.15M -2.91M -2.63M -4.98M -328M -5.11M -34.93M -13.92M -176M -13.14M -12.86M -559M |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/11/26 | US$9.680 | +4.54% | 105,421 |
| 10/11/26 | US$9.260 | +1.87% | 88,184 |
| 09/11/26 | US$9.090 | +8.73% | 46,846 |
| 06/11/26 | US$8.360 | -1.18% | 8,523 |
| 05/11/26 | US$8.460 | -1.74% | 74,073 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- HBIO Stock
Select your edition
All financial news and data tailored to specific country editions
